drugset / Trial / NCT00419146
Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants
Phase 2/3
Completed
99 enrolled
University Hospital, Aker
AstraZeneca · collabDiakonhjemmet Hospital · collabJohanne and Einar Eilertsen's research fund · collabJosef and Haldis Andresen's legacy · collabLaxdale Ltd · collabNorwegian University of Science and Technology · collabScandinavian Society for Psychopharmacology · collabShipowner Emil Stray's legacy · collabSolveig and Johan P. Sommer's foundation · collabStanley Medical Research Institute · collabUniversity of Oslo · collab
RandomizedFactorialQuadruple-blindTreatment
Summary
The purpose of this trial is to study the effect of adding the omega-3 fatty acid EPA and/or Vitamins E + C to antipsychotic drugs in younger patients with schizophrenia and related psychoses.
Timeline
- Start
- 2001-09
- Primary completion
- 2004-04
- Completion
- 2004-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ethyl Eicosapentaenoic Acid | Unknown | 2 g | — |
| Subject | RRR-alpha-tocopherol | Unknown | 392 mg | — |
| Subject | Vitamin C | Other / unclassified | 1000 mg | — |